Wuxi Biologics Revenue (in CNY)
2017: 1.6 Billion
2018: 2.5 Billion
2019: 4 Billion
2020: 5.6 Billion
Has a backlog of orders worth USD 11 Billion+
2017: 1.6 Billion
2018: 2.5 Billion
2019: 4 Billion
2020: 5.6 Billion
Has a backlog of orders worth USD 11 Billion+
Various stages and potential revenue in each stage for a CDMO
Even after increasing their capacity at a rapid pace, Wuxi still has a backlog which is growing at 50% per year.
Imagine the demand for a Biologics CDMO in the industry.
Imagine the demand for a Biologics CDMO in the industry.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
